Can-Fite: Complete response in patient with HCC treated with namodenoson

Can-Fite BioPharma announced that a patient who participated in the Phase II Liver Cancer Study and was treated with namodenoson has a complete response and overall survival of 6.9 years. Liver Cancer designated as hepatocellular carcinoma HCC is a major global health problem due to its incidence, associated mortality, and lack of effective treatment modalities, particularly for patients with advanced hepatic dysfunction known as disease stage Child Pugh B. A patient with advanced HCC that was enrolled in the former Can-Fite Phase II study continues to receive treatment with namodenoson and has now an overall survival of 6.9 years with the disappearance of ascites, normal liver function, and good quality of life and defined as a complete response. Can-Fite has received agreement from both the U.S. Food and Drug Administration FDA and European Medicines Agency EMA on a pivotal Phase III clinical study which is now enrolling patients in Israel, Europe and the US. Namodenoson has Orphan Drug status with both the FDA and EMA, as well as Fast Track Status with the FDA for the treatment of HCC. ..”We are currently enrolling patients for the pivotal Phase III clinical study and hope that if the interim analysis data will be positive, we will be able to get a conditional approval, and that patients who suffer from this devastating disease will enjoy our drug,” stated Can-Fite CEO Motti Farbstein. According to the American Cancer Society, liver cancer accounts for more than 700,000 deaths globally each year.